Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Albiges L, McGregor BA, Heng DYC, Procopio G, de Velasco G, Taguieva-Pioger N, Martín-Couce L, Tannir NM, Powles T. Albiges L, et al. Among authors: de velasco g. Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4. Cancer Treat Rev. 2024. PMID: 37980876 Free article. Review.
PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer.
Santos M, Lanillos J, Caleiras E, Valdivia C, Roldan-Romero JM, Laínez N, Puente J, Beuselinck B, Oudard S, Zucman-Rossi J, Navarro P, Robledo M, Castellano D, de Velasco G, García-Donas J, Rodriguez-Antona C. Santos M, et al. Among authors: de velasco g. Am J Cancer Res. 2023 May 15;13(5):2116-2125. eCollection 2023. Am J Cancer Res. 2023. PMID: 37293154 Free PMC article.
Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L, Colomba E, Romero-Ferreiro C, Cerbone L, Ratta R, Barthelemy P, Vindry C, Fléchon A, Cherifi F, Boughalem E, Linassier C, Fornarini G, Rebuzzi SE, Gross-Goupil M, Saldana C, Martin-Soberón M, de Velasco G, Manneh R, Pernaut C, Sanchez de Torre A, Flippot R, Escudier B, Albiges L. Carril-Ajuria L, et al. Among authors: de velasco g. Eur J Cancer. 2023 Feb;180:21-29. doi: 10.1016/j.ejca.2022.11.013. Epub 2022 Nov 26. Eur J Cancer. 2023. PMID: 36527973
Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial.
de Velasco G, Carril-Ajuria L, Guerrero-Ramos F, Alonso-Gordoa T, Rodríguez-Moreno JF, Carretero A, Martin-Soberon M, de la Rosa-Kehrmann F, Castellano D. de Velasco G, et al. Among authors: de la rosa kehrmann f. Oncotarget. 2022 Aug 4;13:983. doi: 10.18632/oncotarget.28263. Oncotarget. 2022. PMID: 36455393 Free PMC article. No abstract available.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Pal SK, et al. Among authors: de velasco g. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5. Lancet. 2023. PMID: 37290461 Free PMC article. Clinical Trial.
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G. Carretero-González A, et al. Among authors: de velasco g. Oncotarget. 2018 Jan 20;9(9):8706-8715. doi: 10.18632/oncotarget.24283. eCollection 2018 Feb 2. Oncotarget. 2018. PMID: 29492229 Free PMC article.
Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.
Ghanem I, Lora D, Herradón N, de Velasco G, Carretero-González A, Jiménez-Varas MÁ, Vázquez de Parga P, Feliu J. Ghanem I, et al. Among authors: de velasco g. ESMO Open. 2022 Jun;7(3):100485. doi: 10.1016/j.esmoop.2022.100485. Epub 2022 May 14. ESMO Open. 2022. PMID: 35580504 Free PMC article. Review.
118 results